Moshe Talpaz

List of Publications by Citations

405 papers	42,530 citations	96 h-index	200 g-index
422 ext. papers	46,587 ext. citations	6.9 avg, IF	6.71 L-index

#	Paper	IF	Citations
405	Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *New England Journal of Medicine*, **2001**, 344, 1031-7	59.2	4179
404	Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. *New England Journal of Medicine*, **2001**, 344, 1038-42	59.2	2309
403	Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. *New England Journal of Medicine*, **2002**, 346, 645-52	59.2	1693
402	Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. *New England Journal of Medicine*, **2006**, 354, 2531-41	59.2	1414
401	A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. *New England Journal of Medicine*, **2012**, 366, 799-807	59.2	1377
400	Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. *Blood*, **2002**, 99, 3530-9	2.2	986
399	The biology of chronic myeloid leukemia. *New England Journal of Medicine*, **1999**, 341, 164-72	59.2	969
398	Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. *Blood*, **2002**, 99, 1928-37	2.2	850
397	Activating ESR1 mutations in hormone-resistant metastatic breast cancer. *Nature Genetics*, **2013**, 45, 1446-51	36.3	742
396	The molecular genetics of Philadelphia chromosome-positive leukemias. *New England Journal of Medicine*, **1988**, 319, 990-8	59.2	665
395	Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. *New England Journal of Medicine*, **1986**, 314, 1065-9	59.2	594
394	BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. *Blood*, **2003**, 101, 690-8	2.2	574
393	Ponatinib in refractory Philadelphia chromosome-positive leukemias. *New England Journal of Medicine*, **2012**, 367, 2075-88	59.2	556
392	Clinical toxicity of interferons in cancer patients: a review. *Journal of Clinical Oncology*, **1986**, 4, 234-43	2.2	534
391	Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. *Nature Genetics*, **2013**, 45, 180-5	36.3	514
390	Identification of targetable FGFR gene fusions in diverse cancers. *Cancer Discovery*, **2013**, 3, 636-47	24.4	511
389	Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. *Blood*, **2004**, 103, 4396-407	2.2	458

388	Personalized oncology through integrative high-throughput sequencing: a pilot study. *Science Translational Medicine*, **2011**, 3, 111ra121	17.5	452
387	Integrative clinical genomics of metastatic cancer. *Nature*, **2017**, 548, 297-303	50.4	440
386	Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. *Journal of Clinical Oncology*, **2004**, 22, 935-42	2.2	391
385	High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. *Blood*, **2004**, 103, 2873-8	2.2	344
384	Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. *Journal of Clinical Oncology*, **2011**, 29, 789-96	2.2	328
383	Chronic myelogenous leukemia: biology and therapy. *Annals of Internal Medicine*, **1999**, 131, 207-19	8	322
382	Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. *Blood*, **2007**, 109, 4143-50	2.2	321
381	Malignancy-associated Sweet's syndrome: review of the world literature. *Journal of Clinical Oncology*, **1988**, 6, 1887-97	2.2	309
380	Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. *Annals of Internal Medicine*, **1991**, 114, 532-8	8	295
379	Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. *Blood*, **2004**, 103, 3175-84	2.2	277
378	Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. *Clinical Cancer Research*, **2005**, 11, 6924-32	12.9	277
377	Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. *Blood*, **2003**, 101, 473-5	2.2	273
376	Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. *Blood*, **2003**, 102, 987-95	2.2	268
375	Clinical Significance of Cytogenetic Abnormalities in Adult Acute Lymphoblastic Leukemia. *Blood*, **1998**, 91, 3995-4019	2.2	267
374	Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. *Cancer Research*, **2010**, 70, 9265-76	10.1	263
373	Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. *Journal of Clinical Oncology*, **2005**, 23, 3948-56	2.2	259
372	Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. *JAMA - Journal of the American Medical Association*, **2015**, 314, 913-25	27.4	257
371	Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. *Blood*, **2002**, 99, 3547-53	2.2	251

370	Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. *Blood*, **2012**, 119, 1981-7	2.2	249
369	Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. *American Journal of Medicine*, **1990**, 88, 1-8	2.4	243
368	Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. *American Journal of Medicine* , **1987**, 83, 445-54	2.4	241
367	Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. *Clinical Cancer Research*, **2005**, 11, 3425-32	12.9	237
366	Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. *Annals of Internal Medicine*, **2003**, 138, 819-30	8	223
365	Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. *Blood*, **2018**, 132, 393-404	2.2	221
364	Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. *Cancer Cell*, **2015**, 27, 589-602	24.3	212
363	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. *Journal of Hematology and Oncology*, **2017**, 10, 55	22.4	208
362	Characteristics of accelerated disease in chronic myelogenous leukemia. *Cancer*, **1988**, 61, 1441-6	6.4	208
361	Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. *Cancer*, **2003**, 98, 522-8	6.4	200
360	Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. *Cancer Research*, **2004**, 64, 672-7	10.1	199
359	Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. *Blood*, **2003**, 101, 1692-7	2.2	193
358	A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. *Journal of Clinical Oncology*, **1988**, 6, 1328-34	2.2	191
357	Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. *Cancer*, **2003**, 97, 1033-41	6.4	190
356	New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. *Annals of Internal Medicine*, **2006**, 145, 913-23	8	187
355	Pregnancy among patients with chronic myeloid leukemia treated with imatinib. *Journal of Clinical Oncology*, **2006**, 24, 1204-8	2.2	183
354	Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. *Blood*, **2003**, 101, 3794-800	2.2	183
353	Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. *Blood*, **2006**, 108, 1835-40	2.2	181

352	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. *Blood*, **2008**, 111, 1039-43	2.2	175
351	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. *Haematologica*, **2015**, 100, 479-88	6.6	174
350	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. *Blood*, **2014**, 124, 1038-46	2.2	171
349	Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. *Blood*, **2003**, 102, 83-6	2.2	164
348	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. *Lancet Oncology, The*, **2016**, 17, 612-21	21.7	164
347	Homoharringtonine: history, current research, and future direction. *Cancer*, **2001**, 92, 1591-605	6.4	155
346	Getting to the stem of chronic myeloid leukaemia. *Nature Reviews Cancer*, **2008**, 8, 341-50	31.3	151
345	Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. *Journal of Clinical Oncology*, **1995**, 13, 575-82	2.2	151
344	The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. *Virology*, **1985**, 140, 230-8	3.6	149
343	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. *Lancet Haematology,the*, **2017**, 4, e317-e324	14.6	148
342	Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. *Blood*, **2004**, 104, 1979-88	2.2	144
341	Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. *Cancer*, **1999**, 86, 2632-41	6.4	143
340	Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. *Journal of Clinical Oncology*, **2013**, 31, 1285-92	2.2	142
339	Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. *Journal of Clinical Investigation*, **1993**, 92, 1925-39	15.9	140
338	Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. *Blood*, **2007**, 109, 497-9	2.2	137
337	Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. *Blood*, **2002**, 100, 1590-1595	2.2	135
336	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. *JAMA Oncology*, **2018**, 4, 652-659	13.4	133
335	Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. *Journal of the National Cancer Institute*, **2008**, 100, 926-39	9.7	133

334	Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. *Hematology American Society of Hematology Education Program*, **2009**, 461-76	3.1	132
333	Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2018**, 16, 1108-1135	7.3	132
332	Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. *Haematologica*, **2013**, 98, 1865-71	6.6	128
331	Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. *Blood*, **2003**, 101, 97-100	2.2	128
330	Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. *Journal of Clinical Oncology*, **1999**, 17, 284-92	2.2	126
329	Chronic myelogenous leukemia: a review. *American Journal of Medicine*, **1996**, 100, 555-70	2.4	123
328	TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. *Journal of Biological Chemistry*, **2003**, 278, 32317-23	5.4	121
327	Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. *Lancet Haematology,the*, **2019**, 6, e630-e637	14.6	121
326	Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. *Journal of Clinical Oncology*, **1991**, 9, 1241-50	2.2	118
325	Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. *Blood*, **2003**, 102, 4527-34	2.2	117
324	Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. *Cancer*, **2003**, 98, 1905-11	6.4	114
323	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. *New England Journal of Medicine*, **2019**, 381, 2315-2326	59.2	114
322	Severe periorbital edema secondary to STI571 (Gleevec). *Cancer*, **2002**, 95, 881-7	6.4	112
321	Caspase 2 and Caspase 3 Protein Levels as Predictors of Survival in Acute Myelogenous Leukemia. *Blood*, **1998**, 92, 3090-3097	2.2	112
320	Imatinib mesylate causes hypopigmentation in the skin. *Cancer*, **2003**, 98, 2483-7	6.4	111
319	Imatinib mesylate: Clinical results in philadelphia chromosome-positive leukemias. *Seminars in Oncology*, **2001**, 28, 9-18	5.5	109
318	NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2009**, 7, 984-1023	7.3	103
317	Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. *Blood*, **2008**, 111, 1584-93	2.2	103

316	A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. *American Journal of Medicine*, **1990**, 89, 663-72	2.4	103
315	Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. *Blood*, **2011**, 118, 3051-61	2.2	102
314	Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. *Cancer*, **1991**, 68, 1536-7	6.4	102
313	Re-emergence of interferon-□ in the treatment of chronic myeloid leukemia. *Leukemia*, **2013**, 27, 803-12	10.7	99
312	Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. *Leukemia Research*, **2014**, 38, 10-20	2.7	97
311	The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. *Cancer*, **2004**, 100, 116-21	6.4	97
310	Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. *Cancer*, **2003**, 97, 2760-6	6.4	96
309	Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. *Blood*, **2011**, 117, 3151-62	2.2	93
308	Second cancer risk in hairy cell leukemia: analysis of 350 patients. *Journal of Clinical Oncology*, **1997**, 15, 1803-10	2.2	93
307	Sequential Homoharringtonine and Interferon-? in the Treatment of Early Chronic Phase Chronic Myelogenous Leukemia. *Blood*, **1999**, 93, 4149-4153	2.2	93
306	Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. *Blood*, **2005**, 105, 2281-6	2.2	92
305	Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. *Cancer*, **1991**, 67, 990-6	6.4	92
304	Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. *American Journal of Medicine*, **1993**, 94, 69-74	2.4	91
303	Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. *Blood*, **2008**, 111, 3821-9	2.2	90
302	Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. *Annals of Internal Medicine*, **1997**, 127, 186-94	8	88
301	Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. *Leukemia Research*, **2016**, 48, 84-91	2.7	88
300	Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. *Clinical Cancer Research*, **2002**, 8, 2177-87	12.9	84
299	Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. *Journal of Hematology and Oncology*, **2013**, 6, 81	22.4	81

298	BCR rearrangement-negative chronic myelogenous leukemia revisited. *Journal of Clinical Oncology*, **2001**, 19, 2915-26	2.2	79
297	Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. *Cancer*, **2006**, 106, 1306-15	6.4	78
296	NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 1193-1207	7.3	77
295	Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. *Blood*, **2007**, 109, 3470-8	2.2	77
294	Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. *Cancer*, **2003**, 98, 2636-42	6.4	77
293	Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. *Blood*, **2015**, 125, 3588-97	2.2	76
292	Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. *Cancer*, **2007**, 109, 1556-60	6.4	75
291	Should Polymerase Chain Reaction Analysis to Detect Minimal Residual Disease in Patients With Chronic Myelogenous Leukemia Be Used in Clinical Decision Making?. *Blood*, **1999**, 93, 2755-2759	2.2	75
290	Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. *Annals of Internal Medicine*, **1983**, 99, 789-92	8	75
289	Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. *Cancer*, **2003**, 98, 1105-13	6.4	74
288	Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. *Journal of Clinical Oncology*, **2000**, 18, 3513-21	2.2	73
287	Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. *Clinical Cancer Research*, **2002**, 8, 2167-76	12.9	72
286	Loss of Imprinting in Disease Progression in Chronic Myelogenous Leukemia. *Blood*, **1998**, 91, 3144-3147	2.2	71
285	Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. *Journal of Experimental Medicine*, **1993**, 177, 763-74	16.6	71
284	Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. *British Journal of Haematology*, **2004**, 125, 187-95	4.5	70
283	The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. *British Journal of Haematology*, **2013**, 161, 508-16	4.5	69
282	Phenylarsine Oxide Blocks Interleukin-1□Induced Activation of the Nuclear Transcription Factor NF-□B, Inhibits Proliferation, and Induces Apoptosis of Acute Myelogenous Leukemia Cells. *Blood*, **1999**, 94, 2844-2853	2.2	69
281	Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. *British Journal of Haematology*, **1991**, 77, 291-5	4.5	69

280	Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. *Journal of Clinical Oncology*, **1986**, 4, 1101-9	2.2	69
279	The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. *Cancer*, **1987**, 59, 1739-43	6.4	68
278	Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. *Journal of Clinical Oncology*, **2009**, 27, 5015-22	2.2	67
277	Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. *Clinical Cancer Research* , **2003**, 9, 160-6	12.9	67
276	Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. *Haematologica*, **2017**, 102, 327-335	6.6	66
275	Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 3550-5	11.5	65
274	Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. *Blood*, **2006**, 107, 2501-6	2.2	65
273	Methylation of the ABL1 Promoter in Chronic Myelogenous Leukemia: Lack of Prognostic Significance. *Blood*, **1999**, 93, 2075-2080	2.2	65
272	Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. *Blood*, **2016**, 127, 703-12	2.2	65
271	Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. *Blood*, **2010**, 116, 4958-67	2.2	64
270	Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. *Leukemia*, **1997**, 11, 42-7	10.7	64
269	Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. *Clinical Cancer Research*, **2003**, 9, 976-80	12.9	64
268	CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis. *Molecular Cancer Therapeutics*, **2015**, 14, 1717-27	6.1	63
267	Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. *Cancer*, **2003**, 98, 888-93	6.4	62
266	Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. *Blood*, **2001**, 98, 1708-13	2.2	62
265	Chronic myelogenous leukemia: a review and update of therapeutic strategies. *Cancer*, **2003**, 98, 437-57	6.4	61
264	Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. *Cancer*, **2006**, 106, 346-52	6.4	60
263	The role of interferon-alpha in the treatment of chronic myeloid leukemia. *Cytokine and Growth Factor Reviews*, **2007**, 18, 459-71	17.9	60

262	Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. *American Journal of Medicine*, **1995**, 98, 551-8	2.4	60
261	Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. *International Journal of Cancer*, **1996**, 66, 515-9	7.5	59
260	Chronic myelogenous leukaemia: haematological remissions with alpha interferon. *British Journal of Haematology*, **1986**, 64, 87-95	4.5	59
259	Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. *Cancer*, **2002**, 94, 2024-32	6.4	58
258	Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. *Cancer*, **2005**, 103, 2099-108	6.4	57
257	Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. *Blood*, **2016**, 127, 2693-700	2.2	57
256	Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. *Cancer*, **2004**, 101, 332-6	6.4	56
255	Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. *Haematologica*, **2013**, 98, 217-21	6.6	55
254	Pilot study of low-dose interleukin-11 in patients with bone marrow failure. *Journal of Clinical Oncology*, **2001**, 19, 4165-72	2.2	55
253	NF1 inactivation in adult acute myelogenous leukemia. *Clinical Cancer Research*, **2010**, 16, 4135-47	12.9	54
252	Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. *Journal of Clinical Oncology*, **1998**, 16, 1526-31	2.2	54
251	Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. *Cancer*, **1986**, 58, 2023-30	6.4	54
250	Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. *Cancer*, **2004**, 100, 2592-7	6.4	53
249	Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. *Blood*, **2001**, 98, 1773-81	2.2	53
248	Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemia. *Annals of Internal Medicine*, **1986**, 105, 673-9	8	53
247	Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. *Cancer*, **2002**, 94, 2416-25	6.4	52
246	Managing resistance in chronic myeloid leukemia. *Blood Reviews*, **2011**, 25, 279-90	11.1	50
245	Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. *Hematology/Oncology Clinics of North America*, **1998**, 12, 31-80	3.1	49

244	Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. *Clinical Cancer Research*, **2004**, 10, 68-75	12.9	49
243	Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. *Biology of Blood and Marrow Transplantation*, **2001**, 7, 568-75	4.7	49
242	Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma. *Journal of Internal Medicine*, **1993**, 234, 417-20	10.8	48
241	Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. *Blood*, **2003**, 102, 630-7	2.2	47
240	Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance. *British Journal of Haematology*, **1999**, 107, 581-6	4.5	47
239	All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. *Journal of Clinical Oncology*, **1993**, 11, 1489-95	2.2	47
238	Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. *Cancer*, **1995**, 75, 464-70	6.4	47
237	Clinical and prognostic features of patients with Philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary disease. *Cancer*, **1987**, 59, 297-300	6.4	47
236	Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. *Leukemia*, **2021**, 35, 1-17	10.7	47
235	Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. *British Journal of Haematology*, **2013**, 162, 548-52	4.5	46
234	Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. *Mayo Clinic Proceedings*, **2005**, 80, 390-402	6.4	46
233	Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. *Blood*, **2001**, 97, 2846-53	2.2	46
232	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. *American Journal of Hematology*, **2020**, 95, 594-603	7.1	45
231	Interferon-alpha therapy for chronic myelogenous leukemia. *American Journal of Medicine*, **1995**, 99, 402-11	2.4	45
230	Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia. *Cancer*, **1999**, 85, 2583-2588	6.4	44
229	Abnormalities in the PRAD1 (CYCLIN D1/BCL-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell lines. *Cancer*, **1995**, 75, 584-90	6.4	44
228	Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia. *Leukemia Research*, **1995**, 19, 23-34	2.7	43
227	Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. *Cancer*, **1988**, 62, 672-6	6.4	42

226	Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2020**, 18, 1385-1415	7.3	42
225	GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. *Leukemia*, **1998**, 12, 860-4	10.7	41
224	Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. *Cancer*, **2003**, 98, 81-5	6.4	41
223	Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients. *FASEB Journal*, **2000**, 14, 1529-1538	0.9	40
222	Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation. *Journal of Interferon and Cytokine Research*, **1995**, 15, 905-13	3.5	40
221	Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy. *Journal of Clinical Oncology*, **1988**, 6, 1569-75	2.2	40
220	Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFN alpha) therapy. *International Journal of Cancer*, **1985**, 36, 23-8	7.5	40
219	High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. *Leukemia and Lymphoma*, **1998**, 30, 563-71	1.9	39
218	Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. *Cancer*, **1991**, 68, 1201-7	6.4	39
217	Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials.. *Blood*, **2004**, 104, 23-23	2.2	39
216	Philadelphia Chromosome-Negative Chronic Myelogenous Leukemia and Chronic Myelomonocytic Leukemia. *Hematology/Oncology Clinics of North America*, **1990**, 4, 389-404	3.1	38
215	Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. *American Journal of Medicine*, **1988**, 85, 639-44	2.4	38
214	The interferon-alpha revival in CML. *Annals of Hematology*, **2015**, 94 Suppl 2, S195-207	3	37
213	Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. *Cancer*, **2001**, 91, 1964-72	6.4	37
212	Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. *American Journal of Medicine*, **1989**, 86, 554-8	2.4	37
211	Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway. *Oncotarget*, **2014**, 5, 5559-69	3.3	37
210	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. *Oncotarget*, **2017**, 8, 89848-89866	3.3	36
209	Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. *American Journal of Medicine*, **1996**, 100, 452-5	2.4	36

208	Molecular characteristics of chronic myelogenous leukemia in blast crisis. *Cancer Genetics and Cytogenetics*, **1987**, 27, 349-56		36
207	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. *Haematologica*, **2014**, 99, 292-8	6.6	35
206	Degrasyn activates proteasomal-dependent degradation of c-Myc. *Cancer Research*, **2007**, 67, 3912-8	10.1	35
205	Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia--a pilot study. *American Journal of Hematology*, **1987**, 24, 341-50	7.1	35
204	Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. *Blood*, **2014**, 124, 3135-3135	21.3	35
203	A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination. *Cellular Signalling*, **2011**, 23, 2076-85	4.9	34
202	Immune restoration and/or augmentation of local graft versus host reaction by traditional Chinese medicinal herbs. *Cancer*, **1983**, 52, 70-3	6.4	34
201	Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth. *Oncogene*, **2019**, 38, 1576-1584	9.2	34
200	Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma. *Nature Communications*, **2017**, 8, 14449	17.4	33
199	Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. *British Journal of Haematology*, **2002**, 119, 38-45	4.5	33
198	The immune restorative effect of cimetidine administration in vivo on the local graft-versus-host reaction of cancer patients. *Clinical Immunology and Immunopathology*, **1982**, 24, 155-60		33
197	Phase 1 study of the PI3K□inhibitor INCB040093 ⊟ JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. *Blood*, **2018**, 132, 293-306	2.2	32
196	Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. *Journal of Translational Medicine*, **2015**, 13, 294	8.5	32
195	The TNF receptor, RELT, binds SPAK and uses it to mediate p38 and JNK activation. *Biochemical and Biophysical Research Communications*, **2006**, 343, 125-34	3.4	32
194	Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. *Cancer*, **2004**, 100, 2396-402	6.4	32
193	NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2011**, 9 Suppl 2, S1-25	7.3	31
192	Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. *Clinical Cancer Research*, **2005**, 11, 6247-55	12.9	30
191	Imatinib mesylate: Clinical results in Philadelphia chromosome-positive leukemias. *Seminars in Oncology*, **2001**, 28, 9-18	5.5	30

190	MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis. *Blood*, **2019**, 134, 670-670	2.2	30
189	Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. *Clinical Cancer Research*, **2020**, 26, 1247-1257	12.9	29
188	Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia. *Leukemia Research*, **1998**, 22, 341-53	2.7	29
187	Strategies for overcoming imatinib resistance in chronic myeloid leukemia. *Leukemia and Lymphoma*, **2007**, 48, 2310-22	1.9	29
186	Transformation of chronic lymphocytic leukemia to lymphoma of true histiocytic type. *Cancer*, **1995** , 76, 609-17	6.4	29
185	Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients. *British Journal of Haematology*, **1991**, 78, 352-8	4.5	29
184	ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. *Blood Advances*, **2020**, 4, 4282-4291	7.8	29
183	Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). *Journal of Cellular Physiology*, **1996**, 166, 618-30	7	28
182	PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. *PLoS ONE*, **2010**, 5, e11770	3.7	28
181	Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity. *Biochemical Pharmacology*, **2011**, 82, 341-9	6	27
180	Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia. *Cancer*, **1991**, 67, 2959-65	6.4	27
179	Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. *Blood Advances*, **2020**, 4, 5825-5835	7.8	26
178	Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia. *Biochemical Pharmacology*, **2010**, 79, 688-97	6	26
177	Multidrug resistance protein expression in chronic myeloid leukemia **1999**, 86, 805-813		26
176	Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron. *Cancer*, **1987**, 60, 1708-12	6.4	26
175	Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia. *British Journal of Haematology*, **1987**, 67, 55-9	4.5	26
174	Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17, 684-695.e6	2	25
173	Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients. *FASEB Journal*, **2000**, 14, 1529-38	0.9	25

172	Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia. *American Journal of Medicine*, **1992**, 93, 41-8	2.4	25
171	Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study.. *Blood*, **2004**, 104, 1-1	2.2	25
170	The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. *Leukemia*, **2019**, 33, 2924-2933	10.7	23
169	The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. *Leukemia and Lymphoma*, **2005**, 46, 993-7	1.9	23
168	CML: mechanisms of disease initiation and progression. *Leukemia and Lymphoma*, **1993**, 11 Suppl 1, 47-50	1.9	23
167	The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations. *Cancer*, **1995**, 76, 992-7	6.4	23
166	Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation. *Blood*, **2008**, 112, 3232-3232	2.2	23
165	A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial. *Blood*, **2012**, 120, 163-163	2.2	23
164	Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2018**, 16, 1500-1537	7.3	23
163	Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. *Clinical Cancer Research*, **2009**, 15, 3850-5	12.9	22
162	Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha. *Leukemia and Lymphoma*, **1996**, 23, 247-52	1.9	22
161	Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells. *Cancer*, **2002**, 95, 440-50	6.4	22
160	Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. *Cancer*, **2005**, 104, 777-80	6.4	22
159	Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition. *Seminars in Hematology*, **2001**, 38, 22-7	4	22
158	Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: Implications for the treatment of patients with metastatic melanoma. *Cancer*, **1996**, 77, 893-899	6.4	22
157	Therapy of chronic myelogenous leukemia. *Cancer*, **1987**, 59, 664-7	6.4	22
156	Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. *Cancer Chemotherapy and Pharmacology*, **2013**, 71, 1599-607	3.5	21
155	Cellular signalling pathways: new targets in leukaemia therapy. *British Journal of Haematology*, **2002**, 116, 57-77	4.5	21

154	STI-571 in chronic myelogenous leukaemia. *British Journal of Haematology*, **2002**, 119, 15-24	4.5	21
153	Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. *Cancer*, **2003**, 97, 2225-8	6.4	21
152	A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia. *Cancer*, **1991**, 68, 2125-30	6.4	21
151	Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. *Leukemia Research*, **2019**, 79, 38-44	2.7	20
150	Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. *Leukemia Research*, **2003**, 27, 1091-6	2.7	20
149	Serum cytokine levels in infectious mononucleosis at diagnosis and convalescence. *Leukemia and Lymphoma*, **1998**, 30, 583-9	1.9	20
148	Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia. *Cancer*, **1992**, 69, 410-2	6.4	20
147	Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. *Cancer*, **2002**, 94, 2996-9	6.4	19
146	Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. *Cancer*, **2005**, 103, 2551-7	6.4	19
145	Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. *Cancer*, **2001**, 92, 2501-7	6.4	19
144	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. *JAMA Oncology*, **2021**, 7, 525-533	13.4	19
143	The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. *Leukemia Research*, **2018**, 70, 91-96	2.7	19
142	Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015** , 13, 424-34	7.3	18
141	Ponatinib in Philadelphia chromosome-positive leukemias. *New England Journal of Medicine*, **2014**, 370, 577	59.2	18
140	Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients. *American Journal of Clinical Pathology*, **1996**, 106, 442-8	1.9	18
139	Hairy cell leukaemia: review of treatment. *British Journal of Haematology*, **1991**, 79 Suppl 1, 17-20	4.5	18
138	Rheumatoid factors in the sera of patient with gastrointestinal carcinoma. *Cancer*, **1983**, 52, 2156-61	6.4	18
137	Natural history and staging of chronic myelogenous leukaemia. *Best Practice and Research: Clinical Haematology*, **1997**, 10, 277-90		17

136	Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses. *Cancer*, **2003**, 98, 2410-9	6.4	17
135	Therapeutic choices in younger patients with chronic myelogenous leukemia. *Cancer*, **2000**, 89, 1647-58	6.4	17
134	Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 3488-92	11.5	17
133	Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis. *Stem Cells*, **1993**, 11, 112-9	5.8	17
132	Hematologic and Cytogenetic Responses in Imatinib-Resistant Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study.. *Blood*, **2004**, 104, 20-20	2.2	17
131	Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. *Haematologica*, **2017**, 102, 519-528	6.6	16
130	Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. *Cancer*, **2003**, 98, 1430-7	6.4	16
129	Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients. *Journal of Interferon Research*, **1989**, 9, 435-44		16
128	Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study. *Journal of Hematology and Oncology*, **2018**, 11, 101	22.4	15
127	Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia. *Cancer*, **2002**, 94, 1517-21	6.4	15
126	Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies. *Hematology American Society of Hematology Education Program*, **2000**, 90-109	3.1	15
125	The molecular pathology of chronic myelogenous leukaemia. *British Journal of Haematology*, **1991**, 79 Suppl 1, 34-7	4.5	15
124	Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukemia patients and from normal individuals. *Human Gene Therapy*, **1992**, 3, 137-45	4.8	15
123	Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptor. *Blood*, **2001**, 97, 2791-7	2.2	14
122	Current therapy of chronic myelogenous leukemia. *Internal Medicine*, **2002**, 41, 254-64	1.1	14
121	Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha: a synergistic correlation?. *Cancer*, **2000**, 89, 1482-9	6.4	14
120	Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia. *Leukemia and Lymphoma*, **1993**, 10, 407-18	1.9	14
119	Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy. *Cancer Immunology, Immunotherapy*, **1991**, 33, 238-46	7.4	14

118	Pharmacokinetics, Single-Dose Tolerance, and Biological Activity of Recombinant Gamma-Interferon in Cancer Patients. *Oncology*, **1985**, 42, 41-50	3.6	14
117	Dasatinib dose management for the treatment of chronic myeloid leukemia. *Cancer*, **2018**, 124, 1660-1672	6.4	13
116	Apoptosis in chronic myelogenous leukemia: studies of stage-specific differences. *Leukemia and Lymphoma*, **1997**, 25, 121-33	1.9	13
115	Local cutaneous necrotizing lesions associated with interferon injections. *Journal of Interferon and Cytokine Research*, **1998**, 18, 823-7	3.5	13
114	Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery after preparative therapy. The University of Texas M.D. Anderson Cancer Center. Division of Medicine. *Human Gene Therapy*, **1993**, 4, 71-85	4.8	13
113	Treatment of cyclic neutropenia with very low doses of GM-CSF. *American Journal of Medicine*, **1991**, 91, 317-8	2.4	13
112	Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence. *Leukemia and Lymphoma*, **2016**, 57, 2259-67	1.9	13
111	Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation. *Leukemia and Lymphoma*, **1998**, 30, 279-92	1.9	12
110	Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia. *Leukemia and Lymphoma*, **1999**, 35, 483-9	1.9	12
109	What is the contribution of molecular studies to the diagnosis of BCR-ABL-positive disease in adult acute leukemia?. *American Journal of Medicine*, **1994**, 96, 133-8	2.4	12
108	Studies of natural killer cell activity and antibody-dependent cell-mediated cytotoxicity among patients with acute leukemia in complete remission. *Cancer Immunology, Immunotherapy*, **1982**, 14, 96-8	7.4	12
107	Impact of Dose Intensity of Ponatinib on Selected Adverse Events: Multivariate Analyses from a Pooled Population of Clinical Trial Patients. *Blood*, **2014**, 124, 4546-4546	2.2	12
106	Should Polymerase Chain Reaction Analysis to Detect Minimal Residual Disease in Patients With Chronic Myelogenous Leukemia Be Used in Clinical Decision Making?. *Blood*, **1999**, 93, 2755-2759	2.2	12
105	Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth. *Neoplasia*, **2018**, 20, 152-164	6.4	11
104	Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase. *Leukemia and Lymphoma*, **2001**, 41, 309-19	1.9	11
103	Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias.. *Journal of Clinical Oncology*, **2014**, 32, 7084-7084	2.2	11
102	Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy. *Cancer*, **2000**, 88, 570-6	6.4	10
101	A phase I trial of recombinant alpha-2a interferon (Roferon-A) with weekly cisplatinum. *Investigational New Drugs*, **1991**, 9, 37-9	4.3	10

100	A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis. *Tomography*, **2016**, 2, 67-78	3.1	10
99	Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. *Blood*, **2021**, 138, 2042-2050	2.2	10
98	Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I). *Bioorganic and Medicinal Chemistry*, **2014**, 22, 1450-8	3.4	9
97	The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia. *Best Practice and Research: Clinical Haematology*, **1997**, 10, 291-305		9
96	TRAIL-induced cleavage and inactivation of SPAK sensitizes cells to apoptosis. *Biochemical and Biophysical Research Communications*, **2006**, 349, 1016-24	3.4	9
95	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. *Cancer*, **2003**, 97, 3010-6	6.4	9
94	Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia. *Leukemia and Lymphoma*, **2000**, 39, 647-50	1.9	9
93	Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission. *Cancer*, **1991**, 67, 1946-9	6.4	9
92	Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: a potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro. *Annals of Hematology*, **1991**, 63, 297-301	3	9
91	Molecular analysis of retroviral transduction in chronic myelogenous leukemia. *Human Gene Therapy*, **1991**, 2, 317-21	4.8	9
90	Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at M. D. Anderson Cancer Center. *Leukemia and Lymphoma*, **1993**, 11 Suppl 1, 169-74	1.9	8
89	Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials. *Blood*, **2014**, 124, 4552-4552	2.2	8
88	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. *HemaSphere*, **2021**, 5, e562	0.3	8
87	Induction of p53 suppresses chronic myeloid leukemia. *Leukemia and Lymphoma*, **2017**, 58, 1-14	1.9	7
86	Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis. *American Journal of Hematology*, **2017**, 92, 555-561	7.1	7
85	Translocation t(17;18)(q10;q10). *Cancer*, **2001**, 91, 1704-1708	6.4	7
84	Interferon-alpha directly inhibits DNA polymerase activity in isolated chromatin nucleoprotein complexes: correlation with IFN-alpha treatment outcome in patients with chronic myelogenous leukemia. *Gene*, **1995**, 159, 105-11	3.8	7
83	Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial. *Blood*, **2013**, 122, 650-650	2.2	7

82	Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG. *Annals of Hematology*, **2018**, 97, 573-584	3	6
81	Ruxolitinib for the treatment of patients with polycythemia vera. *Expert Review of Hematology*, **2015**, 8, 391-401	2.8	6
80	Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 7194-204	3.4	6
79	Role of interleukin-1 beta converting enzyme (ICE) in acute myelogenous leukemia cell proliferation and programmed cell death. *Leukemia and Lymphoma*, **1997**, 24, 379-91	1.9	6
78	Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors. *Clinical Lymphoma and Myeloma*, **2008**, 8 Suppl 3, S95-S106		6
77	Investigational strategies in chronic myelogenous leukemia. *Hematology/Oncology Clinics of North America*, **2004**, 18, 619-39, ix	3.1	6
76	Cytoplasmic and nuclear localization of the 130 and 160 kDa Bcr proteins. *Leukemia*, **2000**, 14, 1892-7	10.7	6
75	Chromatin nucleoprotein complexes containing tightly bound c-abl, p53 and bcl-2 gene sequences: correlation with progression of chronic myelogenous leukemia. *Gene*, **1996**, 169, 173-8	3.8	6
74	Therapy of chronic myelogenous leukemia with interferon. *Cancer Investigation*, **1989**, 7, 83-91	2.1	6
73	A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF.. *Blood*, **2012**, 120, 2837-2837	2.2	6
72	Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial. *Blood*, **2012**, 120, 3747-3747	2.2	6
71	Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML). *Blood*, **2013**, 122, 652-652	2.2	6
70	Chronic myelogenous leukemia in chronic phase. *Current Treatment Options in Oncology*, **2001**, 2, 245-52	5.4	5
69	Interleukin 4 alters human bone marrow stroma and modulates its interaction with hematopoietic progenitors. *Stem Cells*, **1994**, 12, 638-49	5.8	5
68	New Directions in the Biology and Therapy of Chronic Myeloid Leukemia. *Leukemia and Lymphoma*, **1992**, 6, 89-95	1.9	5
67	The modulatory hematopoietic activities of leukemia inhibitory factor. *Leukemia and Lymphoma*, **1992**, 8, 1-7	1.9	5
66	Therapy of chronic myelogenous leukemia. *Stem Cells*, **1993**, 11 Suppl 3, 8-9	5.8	5
65	Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. *Acta Haematologica*, **1987**, 78 Suppl 1, 70-4	2.7	5

64	Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies. *Hematology American Society of Hematology Education Program*, **2000**, 2000, 90-109	3.1	5
63	Clinical Significance of Cytogenetic Abnormalities in Adult Acute Lymphoblastic Leukemia. *Blood*, **1998**, 91, 3995-4019	2.2	5
62	A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management. *Blood Reviews*, **2021**, 45, 100691	11.1	5
61	Fedratinib Induces Spleen Responses and Reduces Symptom Burden as First-line or Salvage Therapy in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) and Low Platelet Counts. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, S355	2	4
60	Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance. *Leukemia and Lymphoma*, **2006**, 47, 1651-64	1.9	4
59	Activation of class I HLA expression by TNF-alpha and gamma-interferon is mediated through protein kinase C-dependent pathway in CML cell lines. *British Journal of Haematology*, **1991**, 78, 359-67	4.5	4
58	Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia. *Acta Haematologica*, **1990**, 83, 149-51	2.7	4
57	The immune restorative effect of Isoprinosine administration on the local graft-versus-host reaction of cancer patients. *Clinical Immunology and Immunopathology*, **1983**, 28, 96-100		4
56	Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs). *Blood*, **2013**, 122, 1496-1496	2.2	4
55	Tumor necrosis factor related apoptosis inducing ligand (TRAIL) regulates deubiquitinase USP5 in tumor cells. *Oncotarget*, **2019**, 10, 5745-5754	3.3	4
54	A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis. *Blood*, **2021**, 138, 139-139	2.2	4
53	Interleukin-1 increases expression of the LYT-10 (NFkappaB2) proto-oncogene/transcription factor in renal cell carcinoma lines. *Translational Research*, **1998**, 131, 261-8		3
52	Dasatinib Resistance in Patients with Chronic Myelogenous Leukemia: Identification of a Novel bcr-abl Kinase Domain Mutation. *Clinical Leukemia*, **2008**, 2, 267-271		3
51	Mutational Analysis of Chronic Myeloid Leukemia (CML) Clones Reveals Heightened BCR-ABL1 Genetic Instability and Wild-Type BCR-ABL1 Exhaustion in Patients Failing Sequential Imatinib and Dasatinib Therapy.. *Blood*, **2007**, 110, 1938-1938	2.2	3
50	Low-dose interferon-alpha in chronic myeloid leukemia. *Annals of Internal Medicine*, **1995**, 122, 728-9	8	3
49	Oncologists' Use of Genomic Sequencing Data to Inform Clinical Management. *JCO Precision Oncology*, **2018**, 2,	3.6	3
48	Primary myelofibrosis evolving to an aplastic appearing marrow. *Clinical Case Reports (discontinued)*, **2018**, 6, 1393-1395	0.7	2
47	Suppressed formation of bone marrow adherent layers derived from acute myeloid leukemia patients after in vitro exposure to interleukin-4. *Leukemia Research*, **1997**, 21, 519-27	2.7	2

46	DNA in situ hybridization of individual colonies to determine lineage derivation in leukemia. *Leukemia*, **1998**, 12, 242-6	10.7	2
45	Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia. *British Journal of Haematology*, **2008**, 67, 55-59	4.5	2
44	A pilot study of recombinant human interleukin-4 therapy of myelofibrosis. *Journal of Interferon and Cytokine Research*, **1999**, 19, 1253-5	3.5	2
43	Clinical studies of alpha-interferons in chronic myelogenous leukemia. *Cancer Treatment Reviews*, **1988**, 15 Suppl A, 49-53	14.4	2
42	Downregulation of SOX2 by inhibition of Usp9X induces apoptosis in melanoma. *Oncotarget*, **2021**, 12, 160-172	3.3	2
41	Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia. *Cancer*, **1997**, 80, 396-400	6.4	1
40	Molecular approaches to the diagnosis and treatment of cancer. *Stem Cells*, **1993**, 11 Suppl 3, 129-30	5.8	1
39	Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies. *Hematology American Society of Hematology Education Program*, **2000**, 2000, 90-109	3.1	1
38	Integrative Next Generation Sequencing of Myeloproliferative Neoplasms and Correlation of Genetic Variations to Disease Severity. *Blood*, **2018**, 132, 4324-4324	2.2	1
37	Effects of Adaphostin, a Novel Tyrphostin Inhibitor, in Diverse Models of Imatinib Mesylate Resistance.. *Blood*, **2004**, 104, 2097-2097	2.2	1
36	Dasatinib Resistance in CML Patients. Identification of Novel BCR-ABL Kinase Domain Mutation.. *Blood*, **2007**, 110, 1957-1957	2.2	1
35	A New Prognostic Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers. *Blood*, **2014**, 124, 1842-1842	2.2	1
34	Efficacy of HMA +/- Venetoclax or Intensive Chemotherapy in Blast-Phase Myeloproliferative Neoplasms. *Blood*, **2021**, 138, 2569-2569	2.2	1
33	Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. *Blood Advances*, **2021**, 5, 5047-5056	7.8	1
32	Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. *HemaSphere*, **2021**, 5, e553	0.3	1
31	Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. *Leukemia and Lymphoma*, **2019**, 60, 1036-1042	1.9	1
30	Remembering Emil J. Freireich: A Portrait of Courage and Innovation in Cancer ResearchMarch 16, 1927 to February 1, 2021. *Journal of Clinical Oncology*, **2021**, 39, 2973-2976	2.2	1
29	Characteristics of accelerated disease in chronic myelogenous leukemia **1988**, 61, 1441		1

28	SOHO State of the Art Updates and Next Questions: Myelofibrosis. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 191-199	2	0
27	Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM). *Blood*, **2020**, 136, 45-46	2.2	0
26	Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, e201-e210	2	
25	The Interferon Alpha Revival in CML. *Hematologic Malignancies*, **2016**, 207-230	0	
24	Meir Wetzler, MD. *Cancer*, **2015**, 121, 2106-7	6.4	
23	Hematology clinic: chronic myelogenous leukemia. *Hematology*, **2013**, 18, 372-3	2.2	
22	Overcoming resistance in chronic myeloid leukemia. *Clinical Investigation*, **2013**, 3, 817-821		
21	Cell-cycle deregulation in progressive CML. *Nature Reviews Cancer*, **2008**, 8, 563-563	31.3	
20	The Role of Imatinib in the Treatment of Chronic Myelogenous Leukemia. *American Journal of Cancer*, **2004**, 3, 337-348		
19	Genetic therapy of human neoplastic disease. *Stem Cells and Development*, **1993**, 2, 373-5		
18	The Use of Growth Factor Receptor Inhibitors in Human Neoplasms **1994**, 178-195		
17	Identification of a complex formed between nuclear proteins and the transcriptional enhancer of interferon-inducible genes that is present in the peripheral blood myeloid cells of CML but not normal individuals. *Journal of Interferon Research*, **1992**, 12, 323-7		
16	Objective evaluation of local xenogeneic graft-versus-host reaction by computerized radioisotope imaging (CRI). *Journal of Immunological Methods*, **1983**, 61, 133-9	2.5	
15	Inhibition of JAK2/STAT Signaling by Degrasyn through a Novel Mechanism.. *Blood*, **2006**, 108, 3423-3423	2.2	
14	Bortezomib Synergizes with a Novel Jak2 Inhibitor, WP-1130, To Inhibit Cell Growth and Induce Apoptosis in Classic and Blastoid-Variant Mantle Cell Lymphoma.. *Blood*, **2006**, 108, 2512-2512	2.2	
13	Activity of ABL Kinase Inhibitors in Two Distinct Models of Imatinib Resistance.. *Blood*, **2006**, 108, 4819-4819	2.2	
12	A Novel BCR-ABL Mutation Predicts Resistance to Tyrosine Kinase Inhibitor (TKI) Therapy by a Unique Mechanism in Patients (pts) with Philadelphia-Positive (Ph+) Leukemia.. *Blood*, **2006**, 108, 4773-4773	2.2	
11	Lyn Kinase Alters Gab2 Phosphorylation and c-Cbl Protein Levels To Regulate Imatinib Sensitivity and Survival of Chronic Myelogenous Leukemia Cells.. *Blood*, **2006**, 108, 2132-2132	2.2	

10	Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as the Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic Leukemia.. *Blood*, **2007**, 110, 224-224	2.2
9	A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling.. *Blood*, **2007**, 110, 1556-1556	2.2
8	Degrasyn-Induced Trafficking of BCR-ABL as a Novel Mechanism of Kinase Inactivation.. *Blood*, **2007**, 110, 1003-1003	2.2
7	Clinical Studies of Alpha and Gamma Interferons in Chronic Myelogenous Leukemia **1988**, 127-139	
6	Sequential Homoharringtonine and Interferon-? in the Treatment of Early Chronic Phase Chronic Myelogenous Leukemia. *Blood*, **1999**, 93, 4149-4153	2.2
5	Degrasyn (a novel tyrophostin) Impacts BCR-ABL Protein Level and Is Cytotoxic to Chronic Myeloid Leukemia Early Progenitors. *Blood*, **2008**, 112, 3212-3212	2.2
4	Inhibition of Cytokine Signaling through Activation of Jak2 Ubiquitination by WP1130.. *Blood*, **2009**, 114, 2907-2907	2.2
3	De-Ubiquitinase Inhibition by WP1130 Induces Formation of Aggresomes, Engages Autophagy and Activates Apoptosis in B-Cell Malignancies.. *Blood*, **2009**, 114, 3769-3769	2.2
2	WP1130 Inhibits Signaling through BCR-ABL Ubiquitination and Cytoplasmic to Aggresome Trafficking to Induce Apoptosis of CML Cells.. *Blood*, **2009**, 114, 3303-3303	2.2
1	The Interferon-Alpha Revival in CML. *Hematologic Malignancies*, **2021**, 197-226	0